Category: Partners

Signed Partnership Agreement with Long-Term Framework to Support Go-to-Market Plan, Regulatory Progress, and Customer Acquisition Strategy

NEW YORK, NY AND DALLAS, TX / ACCESS Newswire / July 1, 2025 / Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (Nasdaq: GSRT), a publicly traded special purpose acquisition company, today announced that Terra Innovatum has signed a Memorandum of Understanding (“MOU”) with TechSource Inc., an employee-owned science and engineering firm specializing in end-to-end nuclear energy and weapons lifecycle management, advanced scientific R&D, and leadership in the delivery of cutting edge solutions across the federal and commercial sectors. In this partnership TechSource will accelerate the introduction of Terra Innovatum’s SOLO™ micro-modular reactor through supply chain and regulatory advisory support, while expanding access to potential strategic investors, customers and U.S. agency funding programs, including deployment pathways at the U.S. Department of Energy (“DOE”) and Department of Defense (“DOD”).

“This collaboration represents a pivotal milestone in advancing our SOLO™ MMR technology toward full-scale commercialization,” said Alessandro Petruzzi, Co-founder & CEO of Terra Innovatum. “TechSource’s deep network across U.S. governmental agencies, expertise in nuclear material management and U.S. regulatory knowledge will support our regulatory and commercial progress, while bolstering our federal funding and customer acquisition opportunities. Together, we plan to strengthen our connection with industry leaders and national laboratories in the U.S. to build a foundation for the widespread deployment of safe, modular nuclear power. Together, we are fast-tracking SOLO™’s impact on a cleaner, more resilient global energy future.”

“TechSource is proud to partner with Terra Innovatum at this critical inflection point for advanced nuclear innovation,” said V. Brian D’Andrea, Chairman & CEO of TechSource. “Our involvement with nuclear reactor technology dates back to our company’s inception and carries through to today. With decades of experience supporting the Department of Energy, the Department of Defense, national laboratories, and public-sector institutions, we are uniquely positioned to help accelerate the commercialization and deployment of the SOLO™ micro-modular reactor. This collaboration underscores our shared commitment to strengthening national security, advancing safe, scalable nuclear technologies that drive energy resilience, , and delivering technically challenging solution sets across both domestic and international markets.”

Giordano Morichi, Partner, Chief Business Development Officer & Investor Relations of Terra Innovatum stated: “This agreement marks a pivotal step in accelerating the commercial deployment of our technology. TechSource’s unmatched track-record, combined with their expertise in regulatory strategy, stakeholder engagement, and national program execution, makes them an invaluable partner as we bring SOLO™ to market. Together, we’re building not just a deployment plan, but a go-to-market strategy that integrates site development, government partnerships, and industrial adoption. This MOU sets the stage for unlocking real-world opportunities that will move our technology from design to large-scale commercial impact.”

Curtis Christensen, Senior Vice President, West Operations at TechSource, concluded: “This partnership is a natural alignment of vision and capability. Terra Innovatum is pushing the frontier of modular nuclear innovation, and TechSource brings decades of experience delivering complex nuclear programs for federal agencies and international partners. Together, we can accelerate SOLO™’s journey from concept to deployment. Our team is committed to supporting the full lifecycle of this technology-from regulatory approval and site development to stakeholder engagement and long-term operations. We see SOLO™ not just as a reactor, but as a transformative energy solution for critical infrastructure, defense applications, and the global clean energy transition.”

In Picture: A conceptual rendering showcasing four SOLO™ micro-modular reactors (4 MWe / 20 MWt) seamlessly integrated into an off-grid military complex-highlighting the system’s compact footprint, scalability, and potential to deliver clean, reliable power directly at the point of use.

Under the terms of the agreement, Terra Innovatum and TechSource Inc. will work collaboratively on identifying and securing optimal sites for reactor assembly and deployment, optimize supply chain management, support NRC compliance, and engage with key stakeholders-including the DOE, DOD, international laboratories, industry leaders, and institutional end users. The collaboration also paves the way for potential co-investments in operational hubs, advanced manufacturing infrastructure, and strategic R&D partnerships.

ABOUT TERRA INNOVATUM & SOLO^TM

Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 Mwe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: www.terrainnovatum.com.

ABOUT TECHSOURCE INC

Founded in 1997, TechSource is a recognized leader in nuclear science and engineering, comprising more than 500 senior-level scientists, engineers, and industry experts drawn from national laboratories, federal technology programs, and the nuclear industry. The company is widely regarded as an independent, qualified expert, with its advice and solutions trusted as authoritative by clients and their stakeholders.

TechSource consultants bring decades of hands-on experience across the full spectrum of the nuclear material life cycle, including basic and materials research, facility design and operations, weapons programs, material disposition, and systems and operations analysis. Their deep expertise spans particle accelerator design and operation, nuclear power generation, nuclear materials technology, national laboratory initiatives, enterprise and operational IT programs, and complex systems integration.

To learn more, visit: https://techsource-inc.com/.

CONTACTS

Giordano Morichi
Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Srl
E: g.morichi@terrainnovatum.com
W: www.x-solo.com

Nicholas Hresko-Staab
Investor & Media Relations
Alliance Advisors IR
E: TerraIR@allianceadvisors.com

Curtis Christensen
SVP of Operations-West
TechSource
E: cchristensen@techsource-inc.com
W: www.techsource-inc.com

Carrie Holland
VP Marketing and Integrated Communications
TechSource
E: cholland@techsource-inc.com
W: www.techsource-inc.com

IMPORTANT INFORMATION FOR SHAREHOLDERS

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

In connection with the business combination, a Dutch public limited liability company (“Pubco”), GSR III Acquisition Corp. (“GSRT”) and Terra Innovatum s.r.l. (“Terra Innovatum” and, together with GSR III and Pubco, the “Registrant Parties”) have filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT’s ordinary shares in connection with GSRT’s solicitation of proxies for a vote by GSRT’s shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF THE REGISTRANT PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.

Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.

PARTICIPANTS IN THE SOLICITATION

Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

FORWARD LOOKING STATEMENTS

The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC’s declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.

In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to update or revise any forward- looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.

SOURCE: TERRA INNOVATUM SRL

View the original press release on ACCESS Newswire

NORTH YORK, ON / ACCESS Newswire / July 1, 2025 / ZTEST Electronics Inc. (“ZTEST” or the “Company“) (CSE:ZTE)(OTCID:ZTSTF) is pleased to announce that it will be moving from the OTC Pink Sheets to the newly established OTCID market on the OTC Markets Group platform effective July 1, 2025. The Company will continue to trade under the symbol ZTSTF.

The OTCID market requires enhanced reporting obligations, management certifications and company profile updates that give greater accountability and transparency for investors. The transition opens the door to a broader class of institutional and private investors who characteristically require rigorous reporting standards.

The stock will continue to trade without interruption, and no action is required from shareholders during this change.

About ZTEST Electronics Inc.
ZTEST Electronics Inc., through its wholly owned subsidiary Permatech Electronics Corporation (“Permatech”), offers Electronic Manufacturing Services (EMS) to a wide range of customers. Permatech’s offering includes Printed Circuit Board (PCB) Assembly, Materials Management and Testing services. Permatech operates from an ISO 9001:2015 certified facility in North York, Ontario, Canada. Permatech is a contract assembler of complex circuit boards, serving customers in the Medical, Power, Computer, Telecommunications, Wireless, Industrial, Trucking, Wearables and Consumer Electronics markets. It specializes in servicing customers who are looking for high yield and require high quality and rapid-turnaround on low and mid-volume production of high complexity products.

For more information contact: Steve Smith, CEO (604) 837-3751 email: steves@ztest.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR+ in Canada (available at www.sedarplus.com).

SOURCE: ZTEST Electronics Inc.

View the original press release on ACCESS Newswire

MONTREAL, QC / ACCESS Newswire / July 1, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a leading innovator in high-voltage electric marine propulsion systems, today announced it will host a live investor call and webcast to discuss the Company’s acquisition of Nautical Ventures Group Inc.(“Nautical Ventures, named the 2024 Boating Industry Top Dealer of the Year by Boating Industry.

Nautical Ventures has generated over US $100 million in annual revenue from 2020 to 2023, with a strong presence across Florida and national exposure through its boat show attendance, brand portfolio, and digital marketing platform. The acquisition represents a major milestone in Vision Marine’s growth strategy, providing access to a proven retail and service infrastructure and facilitating the market rollout of its E-Motion™ electric powertrain systems.

Event Details:

Wednesday, July 2, 2025, at 11:30 am ET / 8:30 am PT.

The Vision Marine conference call may be accessed as follows:

Webcast URL:

https://www.webcaster4.com/Webcast/Page/3129/52678

Teleconference:

Toll Free: 888-506-0062 International: 973-528-0011

Participant Access Code: 181749

Vision Marine’s management team plans to share insights into how this strategic move supports its broader vision for scaling electric propulsion in the recreational marine industry, enhances operational reach, and positions the Company for long-term growth.

About Vision Marine Technologies Inc.

Vision Marine Technologies Inc. (NASDAQ:VMAR) is a leading innovator in high-voltage electric propulsion systems for the recreational marine industry. The Company’s E-Motion™ powertrain offers OEMs and consumers a scalable, zero-emission, high-performance alternative to internal combustion systems. Vision Marine’s mission is to transform the boating experience through technology, efficiency, and integrated end-to-end electric solutions. Visit: www.visionmarinetechnologies.com

About Nautical Ventures Group, Inc.

Nautical Ventures is an award-winning marine dealership headquartered in Florida, operating nine retail and service locations with global reach. Known for its innovation and bold branding, the company offers a full portfolio of marine products-spanning powerboats, yachts, tenders, catamarans, and electric vessels-supported by factory-trained service and international export capabilities. Nautical Ventures leads the market in real-world adoption of electric propulsion and is the creator of the “Orange is the New Green” campaign. Visit: https://www.nauticalventures.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of U.S. securities laws, including statements related to the strategic, operational, and financial impacts of the acquisition. These statements are subject to risks and uncertainties, including those discussed in Vision Marine’s filings with the U.S. Securities and Exchange Commission. Vision Marine undertakes no obligation to update forward-looking statements except as required by law.

Investor Contact:
Bruce Nurse, Investor Relations
Vision Marine Technologies Inc.
(303) 919-2913
bn@v-mti.com

SOURCE: Vision Marine Technologies Inc

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is forging ahead with advancing its lead candidate NV-387 into Phase II clinical drug development.

NanoViricides has chosen MPox as the first indication to advance NV-387 into Phase II clinical trials out of the four indications for which the Company has substantial efficacy data in animal studies, namely RSV, Influenza, COVID, and Orthopoxviruses (MPox/Smallpox).

The MPox program enables advancing its pipeline towards revenue in the fastest possible manner, the Company believes. The Company intends to advance NV-387 against respiratory infections soon after the Phase II clinical trial of NV-387 for the treatment of MPox infection gets under way.

NanoViricides has already added one Clinical trial Site to the MPox Phase II Program.

A Phase II Clinical Trial Protocol has been developed with the Principal Investigator at this site in the Democratic Republic of Congo (DRC), and this Protocol is undergoing final refinements.

A Clinical Trial Application is in development with many parts having been substantially completed.

NanoViricides has engaged a Clinical Research Organization (CRO) to organize and conduct this Phase II clinical trial for the treatment of MPox with NV-387, as previously stated, and this CRO has organized the Clinical Trial Site and is preparing the CTA with the Company’s inputs.

The manufacture of the drug substance NV-387 is substantially completed at the Company’s own facility. The manufacture of the drug product “NV-387 Oral Gummies” is in progress.

MPox as the first indication has several strategic benefits for the Company.

Firstly, because of the continuing epidemic in the African Region there is a strong need for the drug and also there is the ability to recruit patients and complete the clinical trial in a timely manner. Additionally, running clinical trials in the African Region is substantially less expensive than clinical trials in USA or Europe that the Company has planned for RSV, a commercially important indication with multi-billion dollar potential market.

Secondly, a proof of efficacy in humans of NV-387 against MPox would validate our use of lethal challenge animal models and would establish that our animal model data are predictive of human outcomes. This would have huge implications since our animal model data against every infection we have tested to date has demonstrated NV-387 to be substantially superior to existing drugs, viz. RSV, Influenza, COVID, and of course, MPox/Smallpox.

Thirdly, there is a strong financial case for choosing MPox as the indication. This business case has become even stronger with the failure of tecovirimat (Tpoxx) in clinical trial against MPox. Tecovirimat and brincidofovir (Tembexa) are the only two drugs approved by the US FDA for the treatment of Smallpox, a virus of bioterrorism concern. Both of these drugs were approved under the “FDA Animal Rule”, which eliminates the need for demonstration of efficacy in humans. The “FDA Animal Rule” is applicable for diseases such as Smallpox and others where clinical trials in human patients are not feasible or would be unethical.

These FDA approvals have led to the acquisition of these two drugs into the US Strategic National Stockpile (SNS) to the tune of billions of dollars. And now, there is a clear need for replacing these non-performing drugs with a drug that actually works against MPox and Smallpox (see further down below).

We believe NV-387 would become the choice for addition to the SNS if our proposed Phase II clinical trial against MPox demonstrates benefits of the NV-387 treatment.

The most recent acquisition contracts with BARDA for tecovirimat, which were for drug replenishments, have been valued at over $150million.

An initial stocking contract for NV-387 is likely to be substantially larger, as was the case with the initial acquisition of several drugs into the SNS.

Brincidofovir failed an early clinical trial against MPox due to liver toxicity. Tecovirimat failed a recent clinical trial against MPox since it demonstrated no superiority in efficacy over the standard of care.

Importantly, both of these drug candidates are small chemicals that the viruses can readily escape by mutations. Smallpox, if it ever becomes fielded as a bio-terrorism agent, is unlikely to be in the “original” form of the virus, and could be explicitly manipulated to breed resistance to such small chemical drugs by onerous entities.

Of note, MPox is in the same family as the Smallpox virus; MPox causes a much weaker form of disease than the Smallpox virus.

Thus there is a strong case for HHS to support NV-387 drug development for Bioterrorism Readiness.

The “NV-387 Oral Gummies” drug product is a soft solid formulation that is designed to stick in the oral cavity and dissolve naturally over time, with no solid object (pill or capsule) swallowing necessary. This is important for MPox because MPox causes lesions on mucosal surfaces that make swallowing painful and difficult. MPox is primarily known for the explicit characteristic painful rash on the external skin, but it is a significantly more severe disease than just a skin rash.

The MPox virus circulating in DRC and neighboring regions is of Clade 1a and Clade 1b subtypes, with the latter predominant. Clade 1b is more transmissible of the two, which is why it has resulted in a sustained epidemic. The MPox Clade 1a case fatality rate (CFR) is about 3%-11% whereas the CFR for Clade 1b is about 1%. The MPox Clade 2b is the virus causing continuing cases in the Western world, which causes a much less severe disease than Clade 1a/1b and has a very low CFR, according to CDC. Sporadic cases of Clade 1 in the Western world continue to occur. Four separate travel-related MPox Clade 1 cases reported in the USA that did not result in any further spread, since November 2024, according to the CDC ( https://www.cdc.gov/mpox/situation-summary/index.html ). Clearly, the threat of MPox Clade 1 causing a potential epidemic in the USA cannot be ignored, and readiness with a drug that works against the same is important to achieve.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

ISTANBUL, TR / ACCESS Newswire / June 30, 2025 / Aesthetic operations significantly influence self-confidence and quality of life in today’s environment, when beauty is increasingly individual and comprehensive. Doku Clinic, located in the center of Istanbul, is one of the top institutes in this discipline. The clinic has grown in popularity among patients from all over the world who are looking for exceptional outcomes in body and nose aesthetics because to its skilled staff, cutting-edge equipment, and personalized approach.

Why is Doku Clinic So Popular?

The world-renown of Doku Clinic is due to the direction of two famous doctors:

• Dr. Engin Öcal is a renowned specialist in cosmetic and plastic surgery, particularly in the areas of body contouring and breast augmentation.

• Dr. Serhan Derin is an expert in rhinoplasty surgery and finds the sweet spot between the nose’s aesthetics and its functionality.

The individualized care that patients receive at Doku Clinic is what makes it stand out. Anatomical details, skin type, and aesthetic objectives inform the development of individualized treatment programs for each patient. Every time, you can count on enduring, harmonic, and all-natural results.

Dr. Engin Öcal: A Master of Precision in Shaping Beauty

Breast augmentation, liposuction, stomach tucks (abdominoplasty), and Brazilian butt lifts (BBLs) are just a few of the popular cosmetic operations that improve patients’ physical appearance and sense of self-worth.

With each metamorphosis, Dr. Engin Öcal infuses a creative vision with therapeutic accuracy. Patients who want a natural look that complements their body proportions have come to trust Doku Clinic because of his approach to breast augmentation Turkey.

To guarantee maximum satisfaction, minimal scarring, and quick recovery, Dr. Öcal takes into account each patient’s unique anatomy and lifestyle when choosing implant size, shape, and placement. Restoring one’s femininity and self-esteem are important goals for many people undergoing the operation.

Dr. Serhan Derin’s Functional Beauty Program

Rhinoplasty, which aims to restore nasal airflow while simultaneously improving the patient’s face features, is one of the most intricate and life-altering cosmetic procedures. Renowned for his skill in customizing each nose surgery to match each patient’s unique face anatomy and medical requirements, Dr. Serhan Derin is a frontrunner in this profession.

No matter the kind of rhinoplasty-primary, revision, or ethnic-Dr. Derin always aims to create delicate, natural-looking noses that complement the patient’s overall characteristics. Simultaneously, he fixes any respiratory problems, which greatly enhances quality of life.

His dedication to natural aesthetics and individualized care is right on trend with the current movement away from “overdone” outcomes and toward embracing one’s own unique beauty.

What Made Amanda Du Pont, Alessia Spagnulo, and Priscila Da Silva Choose Doku Clinic for Their Breast Aesthetics? A Global Trust-Building Story

The worldwide influencers who candidly document their beauty adventures on social media have contributed to the growing international prominence of Doku Clinic. These women, who have millions of followers, opted for a single, game-changing operation at Doku Clinic.

Amanda Du Pont, a content producer and actress from South Africa, traveled all the way to Istanbul to have Doku Clinic implant natural breast implants. She was very complimentary of the clinic’s welcoming atmosphere, the exceptional quality of service, and the organic outcomes that Dr. Engin Öcal had accomplished. In an honest review, Amanda praised Doku Clinic and encouraged her followers to make an informed decision.

Italian fashion influencer Alessia Spagnulo has decided to have breast implants at Doku Clinic after much deliberation. Following the treatment, she enthusiastically recounted how it boosted her self-esteem and physical attractiveness. In particular, she lauded the individualized attention and the flattering effect on her figure.

In order to get a more harmonious body type, fitness and lifestyle blogger Priscila Da Silva had breast implants in Turkey. From the initial consultation before the procedure to the healing process, she wrote about how pleasant and reassuring the entire experience was. Doku Clinic, she said, “makes you feel reborn.”

Transforming Your Look Without Incisions: Experience at the Doku Clinic

For people from across the world seeking a unique medical tourism experience, Doku Clinic is more than just a place to get medical treatments done. Airport transportation, hotel stays, translation assistance, pre- and post-operative consultations, and individualized follow-ups are all part of their VIP service packages.

The cutting-edge operating rooms of Doku Clinic prioritize cleanliness and patient safety, and they have received approval from the Ministry of Health to conduct all surgical procedures. Regular check-ins and medical advice ensure that patients are properly followed throughout their recovery process.

Elegance and Self-Assurance, Harmoniously Satisfied

Restoring self-esteem and confidence are two of the many benefits of cosmetic surgery, which goes beyond only improving one’s physical look. Patients are more than simply another number at Doku Clinic; they are companions on a path to healing and personal growth.

Science, artistry, and ethical care come together at Doku Clinic, where patients may have a variety of cosmetic procedures such as breast augmentation, rhinoplasty, body contouring, and non-surgical skin treatments.

Finally, Istanbul’s Most Reliable Spot for Travelers Seeking Beauty

The cosmetic makeover you seek may begin at Doku Clinic if you are seeking natural, balanced, and long-lasting results. As a frontrunner in aesthetic innovation, the clinic has achieved global success in breast aesthetics, achieved technical mastery in nose surgery, and provides an unsurpassed patient experience.

Ready to start your aesthetic journey?

Meet Doku Clinic-where beauty and confidence meet.

Media Contact: Doku Clinic
Email: info@dokuclinic.com
Phone: +90 555 140 04 04
Website: https://www.dokuclinic.com/en
Address: Merkez Mah. İstiklal Sok. No:9 Şişli, İstanbul/Türkiye

SOURCE: Doku Clinic

View the original press release on ACCESS Newswire

By Ovais Riaz & Waa Say – Team Editorial Evrima Chicago

BIRMINGHAM, GB / ACCESS Newswire / June 30, 2025 / The Silent Crisis of Disappearing Languages

In our increasingly globalized world, UNESCO warns that nearly half of all spoken languages are currently endangered, with one disappearing every two weeks. Against this sobering backdrop, educator and author Divya Mistry-Patel has emerged as a passionate advocate for linguistic preservation through her groundbreaking work in children’s literature.

Mistry-Patel is an educator, entrepreneur, and celebrated children’s book author. She has taken a bold step toward making bilingual learning both accessible and engaging.

A Personal Journey Becomes a Cultural Mission

Born into a multicultural Gujarati family in the UK, Mistry-Patel experienced firsthand the gradual erosion of heritage languages in diaspora communities.

“I watched cousins who could understand Gujarati but couldn’t speak it, and eventually children who couldn’t even understand,” she recalls.

This personal observation sparked what would become her life’s work-creating tools to make language learning accessible, engaging, and intergenerational.

Her latest creation, Mari Rang Be Range Biladi (translated as “My Colourful Cat”), represents far more than just another bilingual picture book. It’s a comprehensive language-learning system that includes:

• Dual-language storytelling with culturally rich narratives

• Gujarati alphabet introduction with phonetic guides

• Comprehension exercises designed for family participation

• QR-code linked audiobook for proper pronunciation

• Full English translation for non-Gujarati-speaking parents

• Opportunities to see that diversity is to be celebrated and beauty is within us all

The Growing Demand for Multilingual Education

Recent studies from the University of Chicago demonstrate that bilingual children develop stronger executive function skills, showing 20% greater cognitive flexibility than monolingual peers.

Yet despite these proven benefits, the publishing industry has been slow to respond. A 2022 survey by the Cooperative Children’s Book Center revealed that while 33% of U.S. children come from bilingual homes, only 12% of children’s books published that year offered any non-English content. In the UK, around 20% of children speak or understand more than one language. Furthermore, around half of the world’s population speaks two or more languages.

Mistry-Patel has positioned herself at the forefront of changing this disparity.

“This isn’t just about language retention,” she explains. “It’s about giving children the tools to navigate their multicultural identities with confidence.”

Breaking Barriers in Publishing

The path to bringing Mari Rang Be Range Biladi to market reveals systemic challenges in the publishing industry. Major retailers often relegate bilingual books to “special interest” sections-when they carry them at all. Traditional publishers frequently reject bilingual manuscripts, citing “limited market potential.”

Yet professionals continue to emphasize the importance of encouraging parents to speak in their mother tongue with their children. Research has shown the benefits of bilingual learners, yet this is not reflected on our bookshelves.

In a world where native languages are slowly fading from everyday use, Mistry-Patel is on a mission to ensure cultural heritage and linguistic roots are preserved.

Undeterred, she adopted an innovative hybrid approach:

• Self-publishing to maintain creative control and raise awareness

• Partnering with educational institutions for distribution

• Developing teacher resources to encourage classroom adoption

• Leveraging social media to build direct community support

This strategy has yielded impressive results, with the book gaining traction in both educational circles and Gujarati communities worldwide.

Recognition and Future Horizons

The impact of Mistry-Patel’s work is gaining institutional recognition. She currently holds nominations for:

• Kent Women in Business Awards 2025 (Runner-Up in Innovation Award & Finalist in Women In Education Award)

• The Tutors’ Association Awards (Shortlisted in two categories: Education Resources for Tuition 2025 and Tuition Partner of the Year 2025)

• The Diversity Book Awards (shortlist announcement imminent)

Through her company, Academic Achievements Ltd, she is now developing versions in Punjabi, Hindi, Malayalam, and Tamil-potentially reaching over 500 million native speakers globally.

A recent partnership with local schools and Kent libraries has made the book freely available to local families, with plans for similar initiatives nationwide.

How Readers Can Support the Movement

Mistry-Patel emphasizes that preserving linguistic diversity requires a community effort:

• Request bilingual books at local bookstores and libraries

• Share experiences using #MotherTongueMatters

• Engage with content on Instagram and Facebook

• Participate in virtual reading events

• Gift bilingual books for birthdays and holidays

• Read to your children or listen to audiobooks together

The Ripple Effect of Language Preservation

As linguist Dr. Ananya Sharma notes,

“When we lose a language, we don’t just lose words-we lose entire ways of seeing the world.”

Mistry-Patel’s work represents a vital countercurrent to this loss, creating what educators are calling “the building blocks of cultural continuity.”

With Mari Rang Be Range Biladi available on Amazon and her expanding series underway, Mistry-Patel is proving that one passionate voice can indeed change the narrative-in any language.

Mistry-Patel has more books coming soon in both South Asian languages and in English. The books are all designed to empower young minds and encourage their love for learning. Through Mistry-Patel’s experience in the education sector, her experience over the years has allowed her to create resources with neurodivergent students in mind. Keep up-to-date with the latest resources, services and books created by Academic Achievements Ltd on their socials.

Connect with the Movement

Platform	Details
Website	www.academicachievements.co.uk
Instagram	@academicachievementsltd,@author_divyamistrypatel
Facebook	Academic Achievements
Educational Inquiries	help@academicachievements.co.uk info@academicachievements.co.uk

Disclaimer

This article was authored, developed, and distributed by Evrima Chicago, LLC, serving as the official editorial and media representative for Divya Mistry-Patel, founder of Academic Achievements Ltd and author of Mari Rang Be Range Biladi. This content is released for educational, cultural, and journalistic purposes.

• Evrima Chicago officially represents Divya Mistry-Patel for all media, publicity, and syndication matters related to this article and affiliated literary works.

• The views, insights, and commentary expressed herein are based on interviews, verified statements, and publicly available materials, and reflect the intent to inform and inspire discourse on bilingual education and cultural preservation.

• This article is not legal advice, nor does it reflect the views of any government agency or institutional partner mentioned.

• All statistics, studies, and expert quotes referenced are cited in the Sources & Citations section at the end of this publication.

• Reproduction, excerpting, or redistribution of this content must credit both the author and Evrima Chicago, LLC as the originating editorial source.

• Educators, community leaders, librarians, and institutions are encouraged to use this article as part of broader conversations on multilingualism, diversity, and inclusive learning.

Media & PR Contact

Dan Wasserman
Head of Media & Public Affairs
PR@EvrimaChicago.com
+1 (909) 326-0347
Evrima Chicago – Editorial Syndication Bureau

Sources & Citations

Source	Details
UNESCO Language Endangerment Report	https://www.unesco.org/en/days/mother-language
University of Chicago Study on Bilingualism	Bialystok, E., & Barac, R. (2012). Executive Function and Cognitive Flexibility in Bilingual Children
Cooperative Children’s Book Center 2022 Report	https://ccbc.education.wisc.edu/literature-resources/ccbc-diversity-statistics/
UK Gov Report on Children’s Language Usage	Department for Education, UK (2020)
Dr. Ananya Sharma Quote	Language and Identity Studies, Delhi University Symposium, 2023

SOURCE: Evrima Chicago LLC.

View the original press release on ACCESS Newswire

LAGUNA NIGUEL, CA AND DUBLIN, CA / ACCESS Newswire / June 30, 2025 / Last Mile Solutions (LMS), a high-performance parcel carrier designed for e-commerce, and Orchestro.AI, a logistics intelligence platform transforming delivery decision-making, today announced a strategic partnership to build smarter, more adaptive shipping infrastructure for the modern commerce economy.

LMS operates a flexible, California-compliant logistics network serving high-growth sectors including meal kits, fresh produce, and traditional e-commerce. With consistent next-day service, LMS meets the rising demand for precision, speed, and regulatory alignment in complex urban, suburban, and rural environments across the U.S.

Through this partnership, LMS will embed Orchestro’s intelligence layer into its operations – enhancing network planning, market responsiveness, and decision velocity. Orchestro will also enable integration into third-party systems – including WMS, TMS, OMS, and CRM platforms – to streamline data exchange and execution across the supply chain.

The platform’s predictive capabilities allow LMS to adjust delivery operations based on live weather patterns, traffic disruptions, and localized risk signals such as theft or social unrest. These signals power near real-time communications with customers and help shippers reduce losses tied to delay, damage, and package theft.

The partnership enables LMS delivery stations to move beyond static dashboards and interact directly with their operational data – using conversational AI agents and augmented intelligence to make faster, smarter decisions in real time. Whether resolving a delivery exception or rerouting a driver, these tools bring intelligence to the edge of the network, where timing and context matter most.

“LMS delivers where legacy systems fall short – in sectors that demand both speed and precision,” said Doug Schwartz, CEO and Co-Founder of Last Mile Solutions. “This partnership gives us the visibility and intelligence we need to act decisively – while remaining committed to operational excellence and customer trust.”

Together, the companies will deploy solutions that help LMS grow its customer base, optimize delivery performance, and streamline operations across high-volume markets. The partnership also supports LMS’s expansion into a nationwide delivery network by orchestrating seamless collaboration with national and regional carrier partners – delivering consistent service, intelligence, and value at scale.

“We are architecting a new era of logistics – one where intelligence moves with the network,” said Shekar Natarajan, Founder and CEO of Orchestro.AI. “By partnering with carriers purpose-built for e-commerce, like LMS, we’re transforming how delivery happens at the edge: dynamic, data-driven, and tuned for the speed of modern demand.”

About Last Mile Solutions

LMS is a California-based parcel carrier built for the demands of modern commerce.

LMS Core: LMS’s proprietary next-day delivery network powered by our professional, uniformed, background-checked drivers in commercial delivery vehicles – faster delivery, better service, lower cost.

LMS Reach: LMS’s network of carrier partners, complementing LMS’s Core network to enable fast, cost-effective delivery to 100% of zip codes in the continental U.S.

LMS Lift: Revolutionary middle mile platform, enabling 2-day delivery to over 70% of the US population at rates cheaper than traditional 5-8-day ground competition.

LMS combines speed, regulatory compliance, and operational transparency across a flexible last mile delivery network.

For media inquiries, please contact:
Shekar Natarajan
shekar@orchestro.ai
www.orchestro.ai

About Orchestro.AI
Orchestro.AI is a logistics intelligence platform that turns shipping data, carrier agreements, and fulfillment workflows into real-time decisions. Its AI-driven tools help carriers, shippers, and store networks plan smarter, operate faster, and adapt dynamically to an evolving delivery landscape.

SOURCE: Orchestro.AI

View the original press release on ACCESS Newswire

New index inclusion aligns with company’s domestic growth strategy, including new facility and increased hiring

ORLANDO, FLORIDA / ACCESS Newswire / June 30, 2025 / Unusual Machines, Inc. (NYSE American:UMAC), a leader in drone technology and component manufacturing, announced its inclusion in the Russell Microcap® Index, effective today. The addition reflects the company’s accelerating growth and aligns with its ongoing strategy to scale U.S. operations and strengthen domestic manufacturing capabilities.

“Being added to the Russell Microcap Index marks an important milestone in our growth journey,” said CEO Allan Evans. “It reflects increasing visibility in the market and underscores the strategic steps we’re taking to advance a strong, U.S.-based foundation for long-term success.”

In parallel, Unusual Machines is expanding its U.S.-based workforce to support this next phase of growth, with hiring underway across engineering, operations, and manufacturing roles.

“As we scale, we’re focused on more than just infrastructure-we’re building the team that will power our next chapter,” Evans added. “We’re making targeted investments in areas that drive long-term value, while maintaining a measured approach to capital allocation as we work toward achieving cash flow positivity over the next four to six quarters.”

The announcement follows the company’s recent lease of a 17,000-square-foot drone motor production facility in Orlando, Florida-part of a broader strategy to localize manufacturing, enhance cost efficiency through tariff advantages, and better control quality and lead times. The company’s dual-sourcing approach will allow it to offer both U.S.-made and globally sourced motor variants, providing flexibility to meet regulatory requirements and evolving customer preferences.

Please visit www.unusualmachines.com/careers for the company’s latest job opportunities.

About the Russell Microcap® Index

The Russell Microcap Index includes the smallest 1,000 securities in the Russell 2000® Index, plus the next 1,000 smallest eligible securities by market cap. Inclusion in the index means Unusual Machines will be automatically added to relevant growth and value style indexes used by institutional investors and index funds.

About Unusual Machines

Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot ecommerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032.

For more information, visit www.unusualmachines.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements include: our expectation that our targeted investments will drive long-term value and our expectation that we will achieve cash flow positivity over the next four to six quarters. The results expected by some, or all of these forward-looking statements may not occur. Factors that affect our ability to achieve these results include the impact of and duration of the tariff policies, including (i) Also see the Risk Factors contained in our Form 10-Q, filed with the SEC on May 8, 2025, Prospectus Supplement filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2025 and in our Form 10-K for the year ended December 31, 2024. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Any forward-looking statement made by us herein speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:

CS Investor Relations
investors@unusualmachines.com
917-633-8980

Media Contact:

media@unusualmachines.com

SOURCE: Unusual Machines, Inc.

View the original press release on ACCESS Newswire

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors

Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection

IND-enabling studies underway, with Phase I study initiation expected in 2Q26

Webcast and conference call to be held today at 4:30 pm ET

NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. The triple agonist PN-477 is designed to offer the optimal combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration.

“We are very pleased to nominate development candidate PN-477, a promising potential best-in class oral GLP-1, GIP, GCG receptor tri-agonist peptide which has demonstrated optimal absolute and relative activity against all three hormone receptors in preclinical testing,” said Dinesh V. Patel, PhD, President and CEO of Protagonist. “PN-477 is specifically engineered to be orally stable with attention to the relative balance of potencies against the three receptors to potentially leverage their beneficial effects on weight loss and optimal body composition while mitigating their adverse effects. As with our previous drug candidates and late-stage assets, PN-477 is a testament to the power of our peptide technology platform, including the ability to deliver first- and best-in-class targeted oral and injectable peptide therapeutics.”

PN-477 has completed extensive preclinical evaluation including oral and metabolic stability, potency, pharmacokinetics and pharmacodynamics studies, and has demonstrated effects in preclinical models of obesity and glycemic control. PN-477 has shown potent in vitro activity in activating the GLP-1, GIP, and GCG receptors. PN-477 also demonstrated robust preclinical proof-of-concept in various animal studies including the diet induced obesity (DIO) preclinical mouse model, normal dogs, and cynomolgus monkeys. Overall, PN-477 has the right balance of potency, oral and in-vivo stability, and pharmacokinetic properties to enable parallel development both as a once-daily oral (PN-477o) and once-weekly injectable (PN-477sc) treatment options. IND enabling studies of PN-477 are underway and initiation of Phase 1 clinical studies is anticipated in the second quarter of 2026.

“While GLP-1 agonists have dominated the market thus far, there remains a broad opportunity for novel therapeutics with better body weight loss, higher ratio of fat to lean mass loss, tolerability and additional beneficial effects in obesity-related comorbidities. A triple GLP-1, GIP, GCG receptor agonist peptide that offers weight loss on par with the best injectable treatments options, as well as the optionality provided by both oral and injectable routes of administration, would be an important therapeutic breakthrough and represents another potential blockbuster drug opportunity for Protagonist,” added Dr. Patel. “We look forward to moving PN-477 into first-in human clinical Phase 1 studies in the second quarter of 2026.”

Conference Call and Webcast Details
The dial-in numbers for Protagonist’s investor update on Monday, June 30^th at 4:30 pm ET are:

US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13754335

The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86

A replay of the presentation will be available on the Company’s Investor Relations Events and Presentations webpage following the event.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to J&J Innovative Medicines (“JNJ”), formerly Janssen Biotech, Inc. Following icotrokinra’s joint discovery by Protagonist and JNJ scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and oral hepcidin.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of PN-477, and the timing of PN-477 clinical development. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading “Risk Factors” contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577

Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext. 1

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire